Cargando…

Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer

Oncogenic KRAS mutation plays a key role in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis with nearly 95% of PDAC harboring mutation-activated KRAS, which has been considered an undruggable target. Doublecortin-like kinase 1 (DCLK1) is often overexpressed in pancreatic cancer, and recent stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Dongfeng, Weygant, Nathaniel, Yao, Jiannan, Chandrakesan, Parthasarathy, Berry, William L., May, Randal, Pitts, Kamille, Husain, Sanam, Lightfoot, Stan, Li, Min, Wang, Timothy C., An, Guangyu, Clendenin, Cynthia, Stanger, Ben Z., Houchen, Courtney W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699308/ https://www.ncbi.nlm.nih.gov/pubmed/31467540 http://dx.doi.org/10.1155/2019/6402925

Ejemplares similares

Dclk1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition
por: Chandrakesan, Parthasarathy, et al.
Publicado: (2014)

Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism
por: Sureban, Sripathi M., et al.
Publicado: (2015)

DCLK1 Regulates Pluripotency and Angiogenic Factors via microRNA-Dependent Mechanisms in Pancreatic Cancer
por: Sureban, Sripathi M., et al.
Publicado: (2013)

Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment
por: Cao, Zhiyun, et al.
Publicado: (2020)

DCLK1 Regulates Tumor Stemness and Cisplatin Resistance in Non-small Cell Lung Cancer via ABCD-Member-4
por: Panneerselvam, Janani, et al.
Publicado: (2020)

Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells
por: Chandrakesan, Parthasarathy, et al.
Publicado: (2017)

Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases
por: Ali, Naushad, et al.
Publicado: (2015)

Intestinal tuft cells regulate the ATM mediated DNA Damage response via Dclk1 dependent mechanism for crypt restitution following radiation injury
por: Chandrakesan, Parthasarathy, et al.
Publicado: (2016)

Dclk1(+) small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal
por: Chandrakesan, Parthasarathy, et al.
Publicado: (2015)

DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma
por: Weygant, Nathaniel, et al.
Publicado: (2014)

Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments
por: Wu, Xiangyan, et al.
Publicado: (2020)

Regulatory Roles of Dclk1 in Epithelial Mesenchymal Transition and Cancer Stem Cells
por: Chandrakesan, P, et al.
Publicado: (2016)

Dietary Pectin Increases Intestinal Crypt Stem Cell Survival following Radiation Injury
por: Sureban, Sripathi M., et al.
Publicado: (2015)

Ablation of Doublecortin-Like Kinase 1 in the Colonic Epithelium Exacerbates Dextran Sulfate Sodium-Induced Colitis
por: Qu, Dongfeng, et al.
Publicado: (2015)

Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1
por: Weygant, Nathaniel, et al.
Publicado: (2014)

Doublecortin-Like Kinase 1 Is Elevated Serologically in Pancreatic Ductal Adenocarcinoma and Widely Expressed on Circulating Tumor Cells
por: Qu, Dongfeng, et al.
Publicado: (2015)

Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma
por: Christman, Emily M., et al.
Publicado: (2019)

Fluvastatin Interferes with Hepatitis C Virus Replication via Microtubule Bundling and a Doublecortin-like Kinase-Mediated Mechanism
por: Ali, Naushad, et al.
Publicado: (2013)

Correction: Fluvastatin Interferes with Hepatitis C Virus Replication via Microtubule Bundling and a Doublecortin-like Kinase-Mediated Mechanism
por: Ali, Naushad, et al.
Publicado: (2013)

Inhibition of DCLK1 with DCLK1-IN-1 Suppresses Renal Cell Carcinoma Invasion and Stemness and Promotes Cytotoxic T-Cell-Mediated Anti-Tumor Immunity
por: Ding, Ling, et al.
Publicado: (2021)

DCLK1 autoinhibition and activation in tumorigenesis
por: Cheng, Linna, et al.
Publicado: (2021)

Bufalin Inhibits Tumorigenesis, Stemness, and Epithelial–Mesenchymal Transition in Colorectal Cancer through a C-Kit/Slug Signaling Axis
por: Ding, Ling, et al.
Publicado: (2022)

DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers
por: Sureban, Sripathi M., et al.
Publicado: (2019)

Inflammatory Mediators and Gut Microbial Toxins Drive Colon Tumorigenesis by IL-23 Dependent Mechanism
por: Panneerselvam, Janani, et al.
Publicado: (2021)

Structure-Guided Prediction of the Functional Impact of DCLK1 Mutations on Tumorigenesis
por: Carli, Annalisa L. E., et al.
Publicado: (2023)

DCLK1 Plays a Metastatic-Promoting Role in Human Breast Cancer Cells
por: Liu, Heshu, et al.
Publicado: (2019)

Doublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical β-catenin-dependent mechanism
por: Ali, Naushad, et al.
Publicado: (2020)

Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling
por: Liu, Heshu, et al.
Publicado: (2023)

DCLK1 immunoreactivity in colorectal neoplasia
por: Gagliardi, Giuseppe, et al.
Publicado: (2012)

Analysis of the clinical significance of DCLK1(+) colorectal cancer using novel monoclonal antibodies against DCLK1
por: Dai, Tianqi, et al.
Publicado: (2018)

Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma
por: Liang, Ziwei, et al.
Publicado: (2022)

DCLK1 Suppresses Tumor-Specific Cytotoxic T Lymphocyte Function Through Recruitment of MDSCs via the CXCL1-CXCR2 Axis
por: Yan, Rui, et al.
Publicado: (2022)

Targeting Doublecortin-Like Kinase 1 (DCLK1)-Regulated SARS-CoV-2 Pathogenesis in COVID-19
por: Undi, Ram Babu, et al.
Publicado: (2022)

Structural Basis of Inhibition of DCLK1 by Ruxolitinib
por: Jang, Dong Man, et al.
Publicado: (2021)

Differential Effects of β-catenin and NF-κB Interplay in the Regulation of Cell Proliferation, Inflammation and Tumorigenesis in Response to Bacterial Infection
por: Chandrakesan, Parthasarathy, et al.
Publicado: (2013)

DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma by Remodeling the Epithelial–Mesenchymal Transition Status
por: Yan, Rui, et al.
Publicado: (2023)

Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials
por: Ge, Yang, et al.
Publicado: (2021)

Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases
por: Yarla, Nagendra Sastri, et al.
Publicado: (2020)

Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma
por: Ge, Yang, et al.
Publicado: (2022)

Pleiotropic effects of DCLK1 in cancer and cancer stem cells
por: Chhetri, Dibyashree, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_at73hnuqisu7hkgfpskevnkqll